SynCore Biotechnology Co Ltd (4192) — Cash Flow-to-Debt Ratio
SynCore Biotechnology Co Ltd (4192) has a Cash Flow-to-Debt Ratio of -0.48x as of September 2025, meaning its operating cash flow of NT$-7.18 Million could theoretically repay 0% of its total liabilities (NT$14.88 Million) in one year. See working capital position of SynCore Biotechnology Co Ltd to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SynCore Biotechnology Co Ltd Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for SynCore Biotechnology Co Ltd across 10 annual periods. Also explore SynCore Biotechnology Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for SynCore Biotechnology Co Ltd (2015–2024)
Year-by-year debt coverage analysis for SynCore Biotechnology Co Ltd. For market capitalisation and broader financial context, see market cap of SynCore Biotechnology Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.13x | NT$-49.24 Million | NT$23.11 Million | ▲ +45.1% |
| 2023 | -3.88x | NT$-82.37 Million | NT$21.23 Million | ▼ -247.4% |
| 2022 | -1.12x | NT$-209.61 Million | NT$187.64 Million | ▼ -85.4% |
| 2021 | -0.60x | NT$-229.86 Million | NT$381.52 Million | ▲ +32.8% |
| 2020 | -0.90x | NT$-316.63 Million | NT$353.41 Million | ▲ +67.5% |
| 2019 | -2.76x | NT$-418.57 Million | NT$151.84 Million | ▲ +0.7% |
| 2018 | -2.78x | NT$-272.26 Million | NT$98.11 Million | ▼ -72.1% |
| 2017 | -1.61x | NT$-201.96 Million | NT$125.28 Million | ▼ -22.7% |
| 2016 | -1.31x | NT$-195.09 Million | NT$148.46 Million | ▼ -55.4% |
| 2015 | -0.85x | NT$-156.03 Million | NT$184.46 Million | — |